Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708834 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
A Phase 3 study, sponsored by Biohaven Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 772
- Enrollment target
NCT04708834 is a Phase 3 study that was terminated before completion, run by Biohaven Pharmaceuticals. The registered enrollment target is 772 participants.
The verdict
NCT04708834, a Phase 3 study, was terminated before completion, sponsored by Biohaven Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 772 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
Interventions
- DRUG Troriluzole (BHV-4157)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 772 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708834
The ClinicalTrials.gov registry entry for NCT04708834 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 772 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Troriluzole (BHV-4157) is the first listed.
NCT04708834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04708834 about?
NCT04708834 is a clinical study titled "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder". The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
What is the current status of trial NCT04708834?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 772 participants. The study started on 2021-03-30. Estimated completion is 2026-02-13.
What interventions are being tested in trial NCT04708834?
The interventions under investigation include: Troriluzole (BHV-4157) (DRUG).
Who is sponsoring clinical trial NCT04708834?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.